On a very good Friday for the stock market, Biohaven 's ( BHVN 6.33%) performance was exceptional. The clinical-stage biotech ...

Biohaven stock surged early Friday after the FDA canceled an upcoming meeting to discuss the benefits and risks of its drug, ...

Biohaven (NYSE:BHVN) shares spiked in the premarket on Friday after the FDA revoked an advisory committee meeting scheduled ...

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 ...

More bad news has come down for Biohaven’s small molecule troriluzole. | More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee ...

Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for ...

Biohaven's selective, brain-penetrant TYK2/JAK1 inhibitor, BHV-8000, was selected for an oral presentation at AAN, highlighting the efficacy demonstrated in a human alpha-synuclein overexpressing ...

Biohaven's drug could fill this need, plus, our wait for knowing if they are a contender is only a few days. Moving beyond their migraine candidates, Biohaven has in-place other drug candidates ...

When Biohaven Ltd decoupled from its parent Biohaven Pharma, it retained much of the same management team, and having had tremendous success with its development of Nurtec, and securing an $11.6bn ...

Biohaven, which has a different supplier for commercial production of its treatment Nurtec, says it is working to resolve the issue with the FDA. It has already submitted additional info to the ...

A Biohaven Pharmaceuticals drug developed to treat disease by modulating a neurotransmitter that’s important to normal brain function has failed a pivotal study in a rare neuromuscular disorder ...